SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Acepodia Doses First Patient in Phase 1 ACE723 Trial

ACE723 is the first candidate from Acepodia's AD2C platform to enter human testing.

Related stories